



and



.

14. The compound of any of claims 1 to 13, having the formula:



.

15. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of any of claims 1 to 14.

16. ~~A method of~~Use of a compound of any of claims 1 to 14 in the manufacture of a medicament for treating a disorder or condition through modulating a glucocorticoid receptor~~, the method comprising administering to a subject in need of such treatment, a therapeutically effective amount of a compound of any of claims 1 to 14, thereby treating the disorder or condition.~~

17. ~~A method of~~Use of the compound of any of claims 1 to 14 in the manufacture of a medicament for treating a disorder or condition through antagonizing a glucocorticoid receptor~~, the method comprising administering to a subject in need of such treatment, an effective amount of the compound of any of claims 1 to 14.~~

18. ~~The method~~The use of claim 17, wherein the disorder or condition is selected from the group consisting of obesity, diabetes, cardiovascular disease, hypertension, Syndrome X, depression, anxiety, glaucoma, human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS), neurodegeneration, Alzheimer's disease, Parkinson's disease, cognition enhancement, Cushing's Syndrome, Addison's Disease, osteoporosis, frailty, muscle frailty, inflammatory diseases, osteoarthritis, rheumatoid arthritis, asthma and rhinitis, adrenal function-related ailments, viral infection,

immunodeficiency, immunomodulation, autoimmune diseases, allergies, wound healing, compulsive behavior, multi-drug resistance, addiction, psychosis, anorexia, cachexia, post-traumatic stress syndrome, post-surgical bone fracture, medical catabolism, major psychotic depression, mild cognitive impairment, psychosis, dementia, hyperglycemia, stress disorders, antipsychotic induced weight gain, delirium, cognitive impairment in depressed patients, cognitive deterioration in individuals with Down's syndrome, psychosis associated with interferon-alpha therapy, chronic pain, pain associated with gastroesophageal reflux disease, postpartum psychosis, postpartum depression, neurological disorders in premature infants, and migraine headaches.

19. The ~~method~~use of claim 17, wherein the disorder or condition is selected from the group consisting of major psychotic depression, stress disorders and antipsychotic induced weight gain.